The Type 1 Diabetes Research Consortium, a multi-institutional collaborative program of The Leona M. and Harry B. Helmsley Charitable Trust, held its annual meeting in New York City in October. Established in 2009 to better understand the causes of type 1 diabetes and explore potential therapies, the consortium encompasses 11 institutions and 45 investigators through 28 grants totaling $21.8 million.
HSCI Co-Director Douglas Melton, PhD (far left), is one of four members of the consortium’s Scientific Steering Committee. With Melton are (left to right): committee member Rudy Leibel, MD, Columbia University; Helmsley Charitable Trust Trustee David Panzirer; Program Director Dana Ball; and committee members Matthias Hebrok, PhD, University of California, San Francisco, and Mark Atkinson, PhD, University of Florida.